Citric Acid

Citric Acid

SCHEMBL891608

O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Na+].[Na+].[Zr+4]

nearest known ligand 0.94

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BHRH2IMPA1

The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CA4 P22748 4/20 0.94
CASP1 P29466 1/20 0.36
FFAR3 O14843 1/20 0.32
HDAC3 O15379 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CA2 P00918 1/20 0.31
FAHD1 Q6P587 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Citric Acid SCHEMBL9189671 0.97 CA4 (0.90) CA4CASP1FFAR3HDAC3HDAC1
Citric Acid SCHEMBL276988 0.97 CA4 (1.00) CA4CASP1FFAR3HDAC3HDAC1
Citric Acid SCHEMBL2235356 0.97 CA4 (1.00) CA4CASP1FFAR3HDAC3HDAC1
Citric Acid SCHEMBL3657 0.97 CA4 (1.00) CA4CASP1FFAR3HDAC3HDAC1
Citric Acid SCHEMBL11060179 0.97 CA4 (1.00) CA4CASP1FFAR3HDAC3HDAC1
Citric Acid SCHEMBL215569 0.97 CA4 (0.89) CA4CASP1ALDH1A1
Citric Acid SCHEMBL715802 0.97 CA4 (1.00) CA4CASP1FFAR3HDAC3HDAC1
Citric Acid SCHEMBL25212993 0.94 CA4 (0.94) CA4CASP1FFAR3HDAC3HDAC1
Citric Acid SCHEMBL10692975 0.94 CA4 (0.94) CA4CASP1FFAR3HDAC3HDAC1
Citric Acid SCHEMBL10692967 0.94 CA4 (0.94) CA4CASP1FFAR3HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5217632-A Stirring a mixture of alpha hydroxy carboxylate, a polyol and water to uniformity, adding boric acid or borax to farm chelate and basification ZIRCONIUM TECHNOLOGY CORPORATION (US) 1993-06-08 US claimed
EP-0302544-B1 HIGH TEMPERATURE GUAR-BASED FRACTURING FLUID PUMPTECH N.V. (BE) 1992-06-03 EP claimed
EP-0302544-A2 High temperature guar-based fracturing fluid PUMPTECH N.V. (BE) 1989-02-08 EP claimed
US-4801389-A ZIRCONIUM OR HAFNIUM CROSSLINKING AGENT, BICARBONATE SALT DOWELL SCHLUMBERGER INCORPORATED (US) 1989-01-31 US claimed
US-4624795-A Aqueous acid gels and use thereof BJ-TITAN SERVICES COMPANY (US) 1986-11-25 US claimed
US-20250298177-A1 POLARIZING PLATE AND OPTICAL DISPLAY APPARATUS COMPRISING THE SAME Wuxi Hengxin Optoelectronic Materials Co., Ltd. (CN) 2025-09-25 US disclosed
EP-4601775-A1 METHODS OF MAKING SHAPE STABLE PHASE CHANGE MATERIAL COMPOSITIONS Phase Change Energy Solutions, Inc. (US) 2025-08-20 EP disclosed
EP-3597670-B1 WATER-SOLUBLE COMPOSITION, PRODUCTION METHOD FOR CURED PRODUCT THEREOF, AND CURED PRODUCT THEREOF, AND ACYL PHOSPHINATE ADEKA CORP (JP) 2024-07-10 EP disclosed
WO-2024102900-A1 METHODS OF MAKING SHAPE STABLE PHASE CHANGE MATERIAL COMPOSITIONS PHASE CHANGE ENERGY SOLUTIONS, INC. (US) 2024-05-16 WO disclosed
CN-110036343-B Water-soluble composition, pattern forming agent, method for producing cured product using same, and cured product 株式会社ADEKA 2023-06-13 CN disclosed
US-11649334-B2 Water-soluble composition, production method for cured product thereof, and cured product thereof, and acyl phosphinate ADEKA CORPORATION (JP) 2023-05-16 US disclosed
CN-110337454-B Water-soluble composition, method for producing cured product thereof, and acylphosphinate 株式会社ADEKA 2022-04-12 CN disclosed
US-5268030-A Containing alpha-hydroxycarboxylic acid ligands SEQUA CHEMICALS INC. (US) 1993-12-07 US disclosed
EP-0562821-A1 Paper coating composition containing a zirconium chelate insolubilizer SEQUA CHEMICALS INC. (US) 1993-09-29 EP disclosed
US-5217632-A Stirring a mixture of alpha hydroxy carboxylate, a polyol and water to uniformity, adding boric acid or borax to farm chelate and basification ZIRCONIUM TECHNOLOGY CORPORATION (US) 1993-06-08 US disclosed
US-5182408-A Process for preparation of stable aqueous solutions of zirconium chelates ZIRCONIUM TECHNOLOGY CORPORATION (US) 1993-01-26 US disclosed
EP-0302544-B1 HIGH TEMPERATURE GUAR-BASED FRACTURING FLUID PUMPTECH N.V. (BE) 1992-06-03 EP disclosed
EP-0302544-A2 High temperature guar-based fracturing fluid PUMPTECH N.V. (BE) 1989-02-08 EP disclosed
US-4801389-A ZIRCONIUM OR HAFNIUM CROSSLINKING AGENT, BICARBONATE SALT DOWELL SCHLUMBERGER INCORPORATED (US) 1989-01-31 US disclosed
US-4624795-A Aqueous acid gels and use thereof BJ-TITAN SERVICES COMPANY (US) 1986-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11649334-B2 Water-soluble composition, production method for cured product thereof, and cured product thereof, and acyl phosphinate PHOSPHO1, ASS1, SGMS1 CA4 895/4885CASP1 2001/4885FFAR3 1021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.